CORONARY THROMBOSIS, superimposed on atherosclerotic plaques, occurs in the majority of patients with acute myocardial infarction.' Thrombolytic therapy with streptokinase can result in recanalization of occluded coronary arteries in up to 80% of patients,2-5 but is associated with systemic fibrinolytic activation predisposing to a tendency to bleeding. Although this tendency will result in clinically significant bleeding in only a minority of cases, it complicates surgical intervention within the first few hours after the infusion.
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Tissue-type plasminogen activator (t-PA), which is normally found at very low concentrations in human blood, produces thrombus-specific fibrinolysis by activating plasminogen on the surface of fibrin. In the studies performed thus far it has been shown to be essentially devoid of adverse side effects on the hemostatic system. 6 Although sufficient quantities of t-PA have been obtained from tissue culture media to allow investigations of its biological and thrombolytic properties in small-scale studies,7 it is both difficult and expensive to produce from this source for use in largescale clinical investigations. Recently, Pennica et al. 8 cloned and demonstrated the expression of cDNA of the mRNA for human t-PA in Escherichia coli. In a further development, the cDNA for t-PA was expressed in a mammalian cell system.
The present study details the ability of recombinant human t-PA (rt-PA) from this mammalian cell system to lyse coronary thrombus in an experimental canine preparation of acute myocardial infarction. We report the dose-dependent time to clot lysis, the effects on systemic clotting factors, and the ability of rt-PA to LABORATORY INVESTIGATION-CORONARY THROMBOLYSIS effect a reduction in infarct size when administered early after occlusion.
Materials and methods
rt-PA. rt-PA was obtained by expression of eDNA coding for the entire sequence of melanoma cell-derived t-PA8 in a mammalian cell system. The rt-PA was highly purified to homogeneity from the cell culture fluid in the absence of protease inhibitors and consisted essentially of the two-chain form. It is indistinguishable from melanoma-derived t-PA by a number of physical and biochemical criteria.9 10 The rt-PA used for the present study was devoid of pyrogens.
Experimental preparation. Adult mongrel dogs were anesthetized with pentobarbital (30 mg/kg iv), and received additional doses as required. The dogs were intubated and placed on a respirator. The right carotid artery of each was exposed through an incision in the neck. A modified No. 7-1 Amplatz coronary angiographic catheter was placed in the ascending aorta under fluoroscopy and a blood pressure catheter was placed in the femoral artery. An intravenous catheter was placed in a foreleg vein. Prophylactic antiarrhythmic therapy consisted of 3 mg/min lidocaine (Xylocaine) after an intravenous loading dose of 75 mg. Procainamide, 1.5 g, was also given intravenously.
The chest was opened via a fifth intercostal thoracotomy. A pericardial cradle was fashioned to suspend the heart and epicardial electrocardiographic leads were placed. Blood pressure and the electrocardiogram were continuously recorded. A 1 cm long segment of the left anterior descending coronary artery (LAD) was isolated distal to the septal artery and any high, large diagonal branches. A 0.70 mm (inside diameter) catheter was inserted into a right ventricular side branch of the isolated LAD segment (figure 1). A selective angiogram of the left coronary artery was obtained with the use of 1 to 2 ml of meglumine diatrizoate and recorded on videotape.
Heparin was given as a 100 units/kg iv loading dose and then in 50 units/kg doses to maintain the activated partial thromboplastin time at 1.5 to 2 times baseline. The isolated LAD segment was traumatized by external compression with a blunt forceps to disrupt the endothelium. Snare occlusions were placed proximally and distally on the isolated LAD segment. Thrombin, 0.1 ml at 100 U/ml, was injected via the side-branch catheter into the isolated LAD segment. Citrated fresh canine Additional experiments to demonstrate activation of the fibrinolytic system in vitro by rt-PA during storage of plasma samples. Because significant decreases in fibrinogen, plasminogen, and a2-antiplasmin levels were observed in stored plasma samples taken during rt-PA infusion, but not in plasma samples taken towards the end of the experiment, the following additional experiments were performed to confirm that activation of the fibrinolytic system occurs in vitro in plasma containing high rt-PA levels.
In three animals rt-PA was infused intravenously at a rate of 15 gg/kg/min for 30 min, during which blood samples were taken at 10 min intervals. Subsequent blood samples were then collected at 30 min intervals for 3 hr. Blood samples were collected both into citrate (final concentration O.OIM) and into citrate containing aprotinin (Trasylol; Bayer, Leverkusen, West Germany; final concentration 100 KIU/ml). Fibrinogen levels were measured in whole blood immediately after collection, at the end of the experiment (during which the blood was kept on ice), and in plasma samples stored for 2 hr at 370 C or on ice.
Randomized blinded trial of rt-PA. This study was performed after 30 min of persistent coronary occlusion in 18 dogs subjected to a randomized, blinded trial of intravenous rt-PA at 15 gg/kg/min or saline. Angiography was performed every 10 min during the treatment period or immediately, if evidence of reflow occurred. The "blinded" therapy was infused until either reperfusion occurred and was documented angiographically or until 60 min had elapsed. After treatment was stopped, angiography was performed at 30 min intervals to determine if there was continuing patency or occlusion of the coronary vessel for the 4 hr duration of the experiment.
Pathology. To determine infaret size, at 4 hr each dog was given 500 ml of 2% triphenyl tetrazolium chloride (TTC) via a left atrial injection and killed. 2 The heart was removed and incubated in warm saline for 15 mnin and then fixed in 5% buffered formalin. Each heart was sliced at 1 cm intervals parallel to the atrioventricular groove, photographed, and weighed.
Infarct size was determined morphometrically by planimctry of the TTC-stained slices. Infarct size was expressed as a percentage of left ventricular wall volume. Histologic sections were examined to verify the presence of endothelial trauma in the thrombosed LAD scction and to confirm the presence or absence of thrombus.
Statistical methods. Two random permutations of the integers I to 9 were performed and the first tour of each of these two blocks of integer sets were defined as t-PA treatments and the remaining five as controls. This resulted in a random sequence of treatment assignments with a blocking of 9, so that five control and four t-PA experinments were completed iidway through the trial with similar balance for the remainder of the trial. and 25 ,ug/kg/min of intravenous rt-PA resulted in a time to reperfusion of 13 ± 3 min (n =3). Linear regression analysis of the infusion rate vs time to lysis in the 10 successfully reperfused dogs yielded a correlation coefficient of .88 (p < .001).
The effects of rt-PA dose on relevant parameters of hemostasis are shown in table 1. In samples taken toward the end of the experiments, little evidence of systemic activation of plasminogen, consumption of a2-antiplasmin, or breakdown of circulating fibrinogen was observed. Indeed, the changes in these parameters during the experiment were not significantly different from those observed in the control group. However, in samples taken during rt-PA infusion (not shown) significant alterations were observed most likely as a result of artifactual activation of the fibrinolytic system in vitro (see below). Figure 4 illustrates the rapid rise of plasma t-PA levels to measured peaks within the first 10 min of intravenous rt-PA infusion and the rapid return toward baseline after the infusion was stopped. Mean infusion times for rt-PA were 35 min at 4.3 ,g/ kg/min, 30 min at 10 ,ug/kg/min, 23 min at 15 gg/kg/ min, and 13 min at 25 gg/kg/min.
Epicardicardial ST segment elevation averaged 2.0 + 0.9 mV in all dogs during the 2 hr period of pretreatment occlusion. The ST segments returned to baseline in seven of the 13 dogs in which reperfusion was observed within 60 min. In the 13 dogs in which reperfusion was observed a fall of 1.9 ± 0.9 mV in the ST segment occurred when measured 1 hr after onset of rt-PA infusion. In contrast, the ST segment fell only 0.7 + 0.4 mV on average in the seven control dogs when the segment was measured 3 hr after onset of occlusion (p = .007). Activation of the fibrinolytic system in vitro during storage of blood. Figure 5 summarizes the effect of storage of blood in vitro on the fibrinogen level in one of the three animals. Whereas no changes in fibrinogen levels were observed in the blood samples collected in aprotinin, a progressive drop in level was found in the samples containing a high concentration of rt-PA (during the infusion). Degradation of fibrinogen was not observed when levels were measured immediately after collection of blood samples, but was significant in blood kept on ice until the end of the experiment (3 to 4 hr). In blood samples taken toward the end of the rt-PA infusion (at a time when the plasma rt-PA was greatly reduced as a result of clearance of rt-PA from plasma) no fibrinogen breakdown was observed during storage.
Randomized blinded trial of rt-PA. None of the 10 control dogs receiving saline infusions showed evidence of thrombolysis during the 4 hr experimental period. All of the eight dogs given 15 ,gg/kg/min of rt-PA showed lysis of the LAD thrombus, with a mean 704 15 ,ug/kg/min; 0 -25 .g/kg/min. time to reperfusion of 28 + 3 min. Thus, the total time of LAD occlusion in the rt-PA-treated dogs was approximately 1 hr.
Size of myocardial infarction in the control dogs was 16 ± 2% (mean + SD) of the left ventricle, whereas the mean size of the infarcts in the rt-PA-treated dogs was 2.5 ± 0.5% (p -.001). All infarcts were in the anteroseptal region. Except in one instance, infarcts in the control hearts involved more than half of the thickness of the left ventricular wall and generally showed focal transmural involvement. In contrast, infarcts in the reperfused hearts were most often patchy, subendocardial, and did not show transmural involvement (figure 6). Reperfusion with rt-PA was not associated with significant hemorrhage or edema in the infarct zone.
Blood pressure and electrocardiographic findings were in keeping with results of the dose-response studies.
Discussion
This study was undertaken to investigate the thrombolytic potency of intravenously administered rt-PA in a canine preparation of coronary thrombosis and acute myocardial infarction. The preparation was designed Left, Blood collected in 0.OIM citrate; right, blood collected in 0.01M citrate and 100 KIU/ml of aprotinin. 0 = assay performed immediately on whole blood; 0 = assay performed at the end of the experiment on whole blood kept at 40 C; a = assay performed on plasma stored at 4°C for 2 hr after the end of the experiment; * = assay performed on plasma stored at 370 C for 2 hr after the end of the experiment.
to permit evaluation of thrombolysis of coronary clots without the use of intracoronary thrombogenic foreign materials. In addition it simulated two features of coronary thrombosis that approximate more closely the human situation: endothelial damage and adherence of the thrombus to the arterial wall. The randomized, blinded study confirmed the specific thrombolytic properties of rt-PA and in addition confirmed the earlier findings of Reimer and his colleagues7. 18 that early reperfusion results in a significant reduction of infarct size. Thus, although the observed infarct-sparing effect is not specific for rt-PA, our results show no specific deleterious effects of reperfusion induced by the drug.
In summary, the biological properties of rt-PA permit rapid and predictable coronary thrombolysis without systemic fibrinolysis when the drug is given intravenously. Extrapolation of the results of this study to the clinical setting suggests that the potential of rt-PA therapy to effectively interrupt the process of myocardial infarction will not exclusively depend on its thrombolytic potency but will largely be determined by the time to reperfusion after the onset of coronary thrombolysis.
